The Stromal Vascular Fraction Market To Take An Elliptical Plunge Between 2019 t

Posted by Ashish on May 24th, 2021

Stromal vascular fraction is gaining significant importance in various fields, including internal medicine, orthopaedics, plastic and general surgery, and wound healing.

Ease of harvest, abundant availability, and stable phenotype are some factors increasing the demand for stromal vascular fraction. Also, stromal vascular fraction secretes several soluble factors with anti-inflammatory, immunomodulatory, and analgesic effects, which leads to an alternative treatment option for various diseases, significantly benefitting the growth of the stromal vascular fraction market during the forecast period.

Want Insights To Stromal Vascular Fraction Market? Ask For Sample! https://www.persistencemarketresearch.co/samples/20914

Company Profiles

• Cytori Therapeutics Inc.
• IntelliCell BioSciences Inc.
• Cellular  Biomedicines Group, Inc
• GE Healthcare (Biosafe Group SA)
• Lifecell Corporation (Allergen PLC)
• Tissue Genesis Inc
• InGeneron, Inc.
• Human med AG
• MEDICAN CO., LTD

Delivery of stromal vascular fraction by intra-articular injection has advantages over surgical implantation, such as less invasiveness, better patient compliance, and lower cost.

The global stromal vascular fraction market was valued at US$ 76 Mn in 2018, and is expected to witness a CAGR of around 4% over the forecast period (2019-2029).